Wilson Sonsini Goodrich & Rosati advised LaNova on the deal. Turning Point Therapeutics, Inc., a clinical-stage precision oncology company designing and developing novel targeted therapies for...
LaNova Medicines’ License Agreement with Turning Point Therapeutics
EQRx’s Collaboration with Insilico Medicine
Ropes & Gray advised EQRx in the deal while Wilson Sonsini Goodrich & Rosati represented InSilico. EQRx annlounced a strategic collaboration with Insilico Medicine to jointly...
Cloud Village Inc.’s Spin-Off Listing on HKSE
Freshfields Bruckhaus Deringer has advised the joint sponsors and the underwriters on the offering, while JunHe advised Cloud Village. China International Capital Corporation Hong Kong Securities...
Regor Therapeutics’ $90 Million Series B Financing
Wilson Sonsini Goodrich & Rosati advised Lilly Asia Ventures on the deal. Regor Therapeutics, a clinical-stage biotechnology company dedicated to the discovery of innovative medicines to...
WuXi AppTec’s Acquisition of OXGENE
Wilson Sonsini Goodrich & Rosati and Taylor Wessing advised WuXi AppTec on the deal. WuXi AppTec, a leading global provider of R&D- and manufacturing-enabling services in...